China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of Astellas Pharma’s Nasea (ramosetron) has become the first to pass the generic quality and efficacy consistency evaluation (GQCE) process in China. The product received marketing approval in China in May 2005.
Ramosetron’s Indications and Market Presence
Ramosetron is utilized for the prevention and treatment of gastrointestinal symptoms, including nausea and vomiting, resulting from chemotherapy. The originator drug was first approved in Japan in July 1996 and was introduced to the Chinese market in December 1999. Although there are already 16 generic versions of the drug with the same dosage available in the market, Chongqing Lummy’s version stands out as the first to successfully pass the GQCE process.- Flcube.com
